IUPHAR at WHO



On 21.09.18 the **IUPHAR President**, the **Secretary General** and the Liaison Officer **Dr. Caroline Samer** (Vice chair of IUPHAR Clinical division) had a stimulating meeting at the headquarter of the World Health Organization in Geneva, Switzerland. There was a very constructive conversation with **Dr. Nicola Magrini**, who is responsible scientist for innovation, access and use of essential medicines and health products as well as with **Dr. Shanti Pal**, Group Leader for safety and vigilance. IUPHAR and WHO will continue their collaboration for the next years as IUPHAR is officially recognized as NGO to WHO.

A number of mutual interests were identified among them education in good prescribing and rational pharmacotherapy, assessment and quantification of key drug-drug interactions, an update of the list of essential medicines but also essential pharmacogenetic traits, and contribution to the third WHO Global Patient Safety Challenge: *Medication Without Harm.*
There are many other issues that are of interest from a research but also clinical perspective such as opioids or cannabinoids. The IUPHAR Clinical Division with the clinical mentoring centers and the many experts within the various IUPHAR subcommittees will work on these further. Some initiatives like the IUPHAR pharmacology education programme (PEP) or the collaboration with the British Pharmacological Society's Prescription Skills Assessment (PSA) are excellent tools that should be considered.